News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Oncolytics Biotech Inc. Announces 2012 Year End Results
March 14, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CALGARY, March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (ONC.TO) (ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Oncolytics Biotech Inc.
MORE ON THIS TOPIC
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
July 10, 2025
·
2 min read
·
Tristan Manalac
Series B
Nuclidium Nets $99M Series B for Copper-Based Radiopharma Platform
July 10, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M
July 9, 2025
·
1 min read
·
Dan Samorodnitsky
